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Pancreatic cancer is a disease with an extremely poor prognosis.
Tumor protein 53-induced nuclear protein 1 (TP53INP1) is a proapo-
ptotic stress-induced p53 target gene. In this article, we show by
immunohistochemical analysis that TP53INP1 expression is dramat-
ically reduced in pancreatic ductal adenocarcinoma (PDAC) and this
decrease occurs early during pancreatic cancer development.
TP53INP1 reexpression in the pancreatic cancer-derived cell line
MiaPaCa2 strongly reduced its capacity to form s.c., i.p., and
intrapancreatic tumors in nude mice. This anti-tumoral capacity is,
at least in part, due to the induction of caspase 3-mediated
apoptosis. In addition, TP53INP1/ mouse embryonic fibroblasts
(MEFs) transformed with a retrovirus expressing E1A/rasV12 onco-
proteins developed bigger tumors than TP53INP1/ transformed
MEFs or TP53INP1/ transformed MEFs with restored TP53INP1
expression. Finally, TP53INP1 expression is repressed by the onco-
genic micro RNA miR-155, which is overexpressed in PDAC cells.
TP53INP1 is a previously unknown miR-155 target presenting
anti-tumoral activity.
apoptosis  pancreatic cancer  ponasterone A  tumor suppressor 
micro RNA
Prognosis of pancreatic ductal adenocarcinoma (PDAC) is theworst among cancers, with only 20% of patients reaching two
years of survival. The aggressive nature of the neoplasia, the lack
of early detection, and the limited response to available treat-
ments contribute to its high mortality rate. Pancreatic cancer is
characterized by modifications in gene expression due to muta-
tions, deletions, and amplifications, as well as alterations in DNA
methylation on genes critical for tumor development and pro-
gression (1). Detailed knowledge of genes whose expression is
altered during pancreatic cancer development and of associated
molecular mechanisms may help devising strategies for earlier
diagnosis and identifying new therapeutic targets.
TP53INP1 (tumor protein 53-induced nuclear protein 1) is a
proapoptotic stress-induced p53 target gene (2, 3). TP53INP1 is
able to interact with p53 and the homeodomain-interacting
protein kinase-2 (HIPK2) within the promyelocytic leukemia
nuclear bodies (PML-NBs) modulating p53 transcriptional ac-
tivity (4). TP53INP1 also interacts physically with the proapo-
ptotic protein kinase C  upon exposure to genotoxic agents,
contributing to the regulation of p53 activity during apoptosis
(5). In turn, p53 is able to activate TP53INP1 transcription. p53
exerts its tumor suppressor function mainly by inducing tran-
scription of target genes involved in cell cycle arrest and apo-
ptosis, as part of the cell response to genotoxic stress (2, 6, 7).
Overexpression of TP53INP1 induces cell cycle arrest and apo-
ptosis in several cell lines, even in the absence of p53. In this case,
TP53INP1 is functionally associated with p73 and allows regu-
lation of cell cycle progression and apoptosis, independently
from p53 (8). Finally, the E2F1 transcription factor, also a major
effector of cell proliferation and apoptosis, is involved in
TP53INP1 transcriptional regulation (9). The TP53INP1 gene
encodes two protein isoforms, TP53INP1 and TP53INP1,
which both induce cell cycle arrest and apoptosis when overex-
pressed (2). TP53INP1 expression is lost in rat preneoplastic
lesions in liver (10, 11) and during gastric cancer progression in
human, which correlates with a decreased level of apoptosis in
tumor cells and a poor prognosis (12). Altogether, currently
available data point to a role of TP53INP1 in cellular homeosta-
sis through its antiproliferative and proapoptotic activities.
Therefore, loss of its expression may contribute to deregulation
of cell proliferation, a hallmark of oncogenesis.
In this work, we demonstrate that TP53INP1 expression is lost
in early stages of pancreatic cancer evolution, that its restoration
strongly reduces tumor development, and that TP53INP1 ex-
pression is repressed by a mechanism involving miR-155.
Results
TP53INP1 Inactivation Occurs Early in PDAC Development.Expression
of TP53INP1 was analyzed by immunohistochemistry in healthy
and diseased pancreas tissues by using a specific monoclonal
antibody (clone A25-E12). Positive signal was observed in
normal tissues, in the epithelial layer ducts as shown in Fig. 1A.
Regarding benign pancreatic lesion, TP53INP1 expression was
detected in 100% of mucinous cystadenoma [Fig. 1B and sup-
porting information (SI) Table 1] and intraductal papillary
mucinous neoplasms (IPMN) without dysplasia (Fig. 1C and SI
Table 1). In addition, 97% of chronic obstructive pancreatitis
showed an enhanced cytoplasmic TP53INP1 level in both acinar
and large interlobular ducts cells (Fig. 1D and SI Table 1).
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Conversely, TP53INP1 expression was markedly reduced or
completely lost in the majority of tumoral samples (86%) as
shown in Fig. 1E and SI Table 1. A heterogeneous staining was
observed in the remaining 14% PDAC samples in which only a
limited number of positive cells was observed. In addition,
TP53INP1 expression was not detected in PDAC metastasis
(Fig. 1F and SI Table 1).
The current multistep progression model for PDAC follows
the hyperplasia-dysplasia-invasive adenocarcinoma sequence. In
pancreas, the dysplastic lesions are termed pancreatic intraepi-
thelial neoplasia (PanIN) and are graded from PanIN-1A to
PanIN-3 depending on the intensity of architectural and cellular
atypia (1, 13, 14). We looked at which of these stages TP53INP1
expression was lost by examining the PanIN in the vicinity of 43
invasive PDAC. From 69 PanINs observed (SI Table 1), 24 were
graded as PanIN-1A, 29 as PanIN-2, and 16 as PanIN-3. We
found that TP53INP1 was expressed in all early PanIN-1A
lesions (Fig. 1G and SI Table 1). By contrast, TP53INP1
expression was detected in only 13 of the 29 PanIN-2 (Fig. 1H
and SI Table 1) and in none of the PanIN-3 lesions (Fig. 1I and
SI Table 1). These results suggest that TP53INP1 expression is
partially lost at the PanIN-2 stage and completely in PanIN-3
lesions.
Restored TP53INP1 Expression in Pancreatic Cancer Cells Inhibits
Tumoral Growth in Vivo. To analyze the role of TP53INP1 in
pancreatic cancer development, we developed a TP53INP1-
inducible MiaPaCa2 cell line expressing controlled levels of
TP53INP1 fused to EGFP or of EGFP alone. In this system,
TP53INP1 expression is activated by ponasterone A (PonA).
Vehicle-treated cells do not show any signal upon direct f luo-
rescence microscopic or Western blot analysis, indicating that
there is no leakage of TP53INP1 or EGFP expression. On the
contrary, after treating the cells with PonA, we observed rapid
TP53INP1 induction (Fig. 2 A and C). MiaPaCa2 cell line was
chosen because it does not express endogenous TP53INP1 as
evidenced by RT-PCR and Western blot analysis (data not
shown).
In the absence of PonA, the TP53INP1-inducible MiaPaCa2
cell line generates tumors after s.c., i.p., or intrapancreatic
injections in nude mice. After PonA treatment, epif luorescence
of the EGFP-tag allowed controlling that TP53INP1 was indeed
expressed in tumors (Fig. 2B). To assess the significance of
TP53INP1 restoration in tumoral development, inducible Mi-
aPaCa2 cells were injected s.c. or i.p. in nude mice carrying
vehicle or PonA implants (n  6). In the absence of PonA, mice
injected s.c. developed tumors after 7 weeks, with a mean volume
of 185 56 mm3, whereas none of PonA-treated mice developed
tumors (Fig. 2D). In the same way, TP53INP1-inducible cells
injected i.p. developed tumors that extended to the peritoneal
cavity in 83% of vehicle-treated mice (n 6) whereas no tumors
appeared in PonA-treated mice (Fig. 2F). To assess the influ-
ence of PonA itself on tumoral development, EGFP-inducible
MiaPaCa2 cells were injected s.c. or i.p. in nude mice treated or
not with PonA-releasing implants. We observed that these two
treatments do not induce significant differences in tumor devel-
opment (data not shown). This result indicates that PonA does
not have any effect on this model of tumoral development.
Finally, to study the role of TP53INP1 restoration in the
pancreatic environment, inducible MiaPaCa2 cells were injected
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Fig. 1. TP53INP1 expression is lost in PDAC and metastasis. Shown is
TP53INP1-positive immunostaining in epithelial cells of large ducts from nor-
mal pancreatic tissue (A), mucinous cystadenoma (B), intraductal papillary
mucinous neoplasm (C), and in chronic pancreatitis (D). TP53INP1 protein was
not detected in PDAC (E) and in liver metastasis (F). (G–I). TP53INP1 positive
staining in early lesions, PanIN-1A (red arrow) negative staining in PanIN-1B,
PanIN-2 and PanIN-3 (black arrow).
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Fig. 2. TP53INP1-inducible expression in MiaPaCa2 cells and inhibition of s.c.
and i.p. tumor growth. (A) TP53INP1- or EGFP-inducible MiaPaCa2 cells were
cultured in the presence of PonA 10 M or vehicle as control. Sixteen hours
later, cells were tested for TP53INP1-EGFP or EGFP expression with an anti-
EGFP antibody. (B) Cells were injected into the pancreas of mice, and 2 weeks
later PonA-releasing pellets were implanted. After 48 h, TP53INP1 induction
was visualized by green epifluorescence. (C) TP53INP1-inducible MiaPaCa2
cells were incubated with increasing concentrations of PonA for 48 h (Upper).
Cells were treated for the indicated times with PonA 10 M and TP53INP1
expression was analyzed by Western blot (Lower). -tubulin level was used as
loading control. (D) Ten millions of TP53INP1-inducible MiaPaCa2 cells were
s.c. injected in mice carrying PonA (n  6) or vehicle (n  6) releasing pellets.
Tumoral volume was weekly determined as described in SI Materials and
Methods. (E) Histological analysis of s.c. and i.p. tumors from vehicle-treated
mice. (F) Ten millions of TP53INP1-inducible MiaPaCa2 cells were i.p. injected
in mice carrying PonA (n  6) or vehicle (n  6) releasing pellets. Repre-
sentative photographs are shown. Values are represented as mean  SE.
*, P  0.05.
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into the pancreas of nude mice implanted s.c. with PonA or
vehicle releasing pellets (n  7). Nineteen days after cells
injection, we observed that all vehicle-treated mice developed
intrapancreatic tumors whereas only 43% of the PonA-treated
mice were positive for intrapancreatic tumor. Mean size of
tumors was 55  36 mm3 or 0.5  0.3 mm3 for vehicle or
PonA-treated mice respectively (Fig. 3A). Moreover, tumors
expressing TP53INP1 showed significantly less extrapancreatic
tumoral extension to proximal (Fig. 3B) and distal organs,
indicating that TP53INP1 expression affects the growth and the
spreading of pancreatic cancer cells.
To analyze the putative proapoptotic effect of TP53INP1
expression in these tumors, we measured the presence of active
caspase-3 by immunohistochemistry in intrapancreatic tumors.
TP53INP1-inducible PonA-treated tumors showed a positive
area for active caspase-3 significantly higher than vehicle-treated
tumors (38  4% vs. 21.5  4%). On the other hand EGFP-
inducible tumors treated with vehicle or PonA showed levels of
activated caspase-3 similar to TP53INP1-inducible tumors
treated with vehicle (18 4% and 20.5 2% vs. 21.5 4%) (Fig.
3C). These results suggest that apoptosis contributes to the
inhibition of tumor development observed with TP53INP1-
expressing cells and that this difference is not due to PonA itself.
E1A/ras-TP53INP1/ Mouse Embryonic Fibroblasts (MEFs) Promote
the Formation of Bigger Tumors Than E1A/ras-TP53INP1/MEFs. To
confirm the role of TP53INP1 in another cellular model, MEFs
were derived from E14.5 TP53INP1/ or TP53INP1/ mouse
embryos.MEFs were then infected with a retrovirus allowing the
expression of E1A and rasV12 oncogenes to transform them
(E1A/ras-MEFs). E1A/ras-TP53INP1/ and TP53INP1/
MEFs expressed equivalent high levels of ras as estimated by
Western blot analysis (data not shown). It is noteworthy that the
lack of TP53INP1 expression significantly increases the growth
in E1A/ras-MEFs (Fig. 4C). To restore TP53INP1 expression,
E1A/ras-TP53INP1/MEFs were transduced with the MSCV-
TP53INP1-Myc retrovirus. Endogenous and restored TP53INP1
levels were controlled by Western blot analysis. (Fig. 4B and SI
Fig. 6). Interestingly, TP53INP1 reexpression reduced signifi-
cantly the growth rate of E1A/ras-TP53INP1/MEFs (Fig. 4C).
The tumorigenic properties of E1A/ras-TP53INP1/ MEFs,
E1A/ras-TP53INP1/MEFs and E1A/ras-TP53INP1/MEFs
reexpressing TP53INP1 were assessed. We checked their ability
to grow in an anchorage independent medium in vitro and to
form s.c. tumors in nude mice in vivo. In soft-agar assays,
E1A/ras-TP53INP1/MEFs formed bigger colonies than E1A/
ras-TP53INP1/ MEFs or E1A/ras-TP53INP1/ MEFs reex-
pressing TP53INP1 (Fig. 4D). Similarly, E1A/ras-TP53INP1/
MEFs developed bigger tumors in all nude mice than E1A/ras-
TP53INP1/ MEFs when injected s.c. (Fig. 4 E and F Left).
Moreover, E1A/ras-TP53INP1/ MEFs reexpressing
TP53INP1 developed smaller tumors than E1A/ras-
TP53INP1/MEFs (Fig. 4 E and F Right). These results are in
agreement with the results obtained with TP53INP1-inducible
MiaPaCa2 cells and support the idea that TP53INP1 plays a role
in the prevention of tumor establishment and/or development.
miR-155 Interacts with the TP53INP1 mRNA 3 UTR. TP53INP1 ex-
pression is strongly decreased in pancreatic cancer cells. Because
TP53INP1 expression seems to be important for pancreatic
cancer development, we decided to analyze the molecular mech-
anism by which TP53INP1 expression is lost. We compared the
methylation status and the presence of mutations in the
TP53INP1 promoter in PDAC and peritumoral pancreas (PTP).
No differences were found (data not shown). Then, we quanti-
fied the TP53INP1 mRNA level by RT-PCR in 11 samples
known to be negative for TP53INP1 immunostaining and in their
corresponding (TP53INP1-positive) peritumoral regions. To our
surprise, TP53INP1 mRNA levels were similar in the PADC and
in the PTP whereas the protein was present in PTP and almost
undetectable in PADC (Fig. 5A). These findings suggested that
TP53INP1 down-regulation is not due to a transcriptional mod-
ulation. We therefore made the hypothesis that loss of
TP53INP1 expression could be due to down-regulation by a
miRNA. Bioinformatic approaches were used to identify poten-
tial micro RNA (miRNA) targets in the TP53INP1 mRNA 3
UTR. Interrogation of the TargetScan database (15) revealed,
with the highest scores, the presence of 4 putative sites for
miRNA targeting corresponding to miR-155, miR-190, miR-182,
and miR-504. However, we focused our analysis on miR-155
because it exhibits a high degree of complementarity with the
1217–1243 region in the TP53INP1 3 UTR (Fig. 5B), it is
overexpressed in pancreatic cancer cells (16, 17) and it has been
described to be oncogenic (18, 19). miR-155 level was measured
by RT-PCR on PDAC and PTP. As was already observed by
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Fig. 3. TP53INP1 restoration inhibits tumoral growth in a pancreatic cancer
model in vivo. Eighteen millions of inducible MiaPaCa2 cells were injected into
the pancreas of nude mice (n  7 for each group) one day after s.c. implan-
tation of pellets releasing vehicle as control (V) or PonA (P). Assessment of
pancreatic tumor growth and spreading was done 19 days after cells injection.
(A) (Left and Center) Representative photographs of pancreatic tumors.
(Right) Intrapancreatic tumoral volume (tumor sizes were measured as de-
scribed in SIMaterials andMethods). (B) (Left) Representative images showing
the spreading of pancreatic tumors in PonA and vehicle treated animals (Sp,
spleen; Pa, pancreas). (Center) Representative images of HES-stained pancreas
and spleen from vehicle and PonA-treated animals. Tumor surface is outlined
in black and indicated by arrows. (Right) Representation of the proximal
extension index. The index was determined as described in SI Materials and
Methods. (C) (Left and Center) Representative images of pancreatic tumors
active caspase-3 immunohistochemistry on vehicle and PonA-treated animals
with TP53INP1-inducilbe MiaPaCa2 or EGFP-inducible MiaPaCa2 tumors.
(Right) The percentage of tumor surface containing active caspase-3. Values
are represented as mean  SE. *, P  0.05.
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others (16, 17) miR-155 was overexpressed in the majority of
PDAC samples (Fig. 5A). To validate experimentally computa-
tional data, the TP53INP1 3UTR (i.e., 4777 bp) was subcloned
down-stream of the f-Luciferase ORF in the direct (533) and
in the reversed orientation (335) as control (Fig. 5C). These
reporter constructs were cotransfected in 293T cells with either,
the pEGFP-N1 plasmid (to normalize transfection efficiency)
and the miR-155 or a miR-control (nontargeting RNA oligonu-
cleotide). Interestingly, Luciferase activity was markedly re-
duced only in the cells cotransfected with the miR-155 and the
TP53INP1 3 UTR in the direct orientation (Fig. 5D Left). The
Luciferase activity drop was dose-dependent and showed a 9%
reduction in the presence of only 1 nM of miR-155, reaching a
reduction of 33% when concentration was raised to 25 nM. No
significant reduction of Luciferase activity was observed in
controls (Fig. 5D Right). It was concluded that miR-155 could
target the TP53INP1 3 UTR. To validate this result with
endogenous TP53INP1 expression, MCF7 cells were transfected
with miR-155 and the TP53INP1 protein level was evaluated by
Western blot 36 h later. To induce a detectable expression of
TP53INP1 inMCF7, cells were transfected with a p53-expressing
vector (pcDNA3-p53) and 24 h later they were irradiated at 30
Gy (gamma irradiation) as described by Okamura (6). miR-155
or miR-control was cotransfected with pcDNA3-p53. As shown
in Fig. 5E mir-155 inhibits the expression of endogenous
TP53INP1. To investigate whether inhibition of miR-155 allows
the reexpression of TP53INP1 and induces cell death, pancreatic
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Anti-miR-control and gamma-irradiated (30 Gy), TP53INP1 level was evalu-
ated by Western blot. -tubulin level was used as control. Capan2 cells
transfected with a plasmid allowing the expression of TP53INP1 were mi-
grated in parallel as molecular weight control (M). (G) Apoptosis was mea-
sured in Capan2 cells 24 h after transfection with Anti-miR-155 or Anti-miR-
control.
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Capan2 cells were transfected with an oligonucleotide able to
inhibit the miR-155 activity (anti-miR-155) or a control oligo-
nucleotide. As expected, cells transfected with anti-miR-155
reexpressed TP53INP1 (Fig. 5F) and showed a significant in-
crease in apoptosis (Fig. 5G). Altogether, these results demon-
strate that TP53INP1 is a target of miR-155.
Discussion
The development of invasive PDAC involves the deregulation of
numerous genes and the subsequent transformation of cells in
noninvasive precursor lesions into cancer cells (1). However, in
this cancer, the morphological modifications that occur during
tumor progression have poor diagnostic value (20, 21) and
finding markers that could help identifying high-risk lesions
would be extremely useful. Here we show that TP53INP1 is
present in nonmalignant human pancreatic lesions, is signifi-
cantly or completely lost in the majority of primary PDAC and
is absent in metastasis. The fact that TP53INP1 is lost or, at least,
strongly reduced in a large proportion of tumors and that such
reduction correlates with tumor progression suggests that
TP53INP1 level reduction might be an indicator of pancreatic
malignancy. We propose to include TP53INP1 in the list of
PDAC markers known to be involved in pancreatic adenocar-
cinoma evolution (K-ras, p53, DPC, PSCA, epithelial apomucins,
Cyclin D1, and PMP22) (22–24). To date, distinguishing before
surgery lesions that could degenerate into invasive malignancy
from benign lesions remains a problem to the clinician (25).
TP53INP1 departs from previous markers because its expression
is almost ‘‘all or none’’ between benign and precancerous
pancreatic lesions, which makes TP53INP1 immunohistochem-
istry a previously undescribed tool to distinguish low risk from
high-risk pancreatic affections. Assessing TP53INP1 presence
before surgery by fine-needle aspiration (26) or brush cytology
(27) should allow differential diagnosis of benign features
(strong TP53INP1 level) from malignant transformation at an
early stage (absence or low level of TP53INP1).
On a functional standpoint, the possibility that TP53INP1
repression contributes to PDAC formation is extremely inter-
esting. Significant reduction or loss of TP53INP1 expression was
also detected during the progression of adenocarcinoma of the
stomach (12), colon (unpublished results) and in pancreatic and
intestinal endocrine tumors (S.G., unpublished data). Also, we
recently showed that mice deficient for TP53INP1 presented
with exacerbated colitis-associated carcinogenesis (28). These
observations suggest that, besides pancreas, loss of TP53INP1
expression might be a general feature of carcinoma development
which, as such, deserves being investigated further in other
epithelial tumors.
In this work we used a model of PonA-dependent conditional
TP53INP1 expression to show that a pancreatic cell line (Mi-
aPaCa2), which do not express TP53INP1 and can form tumors
in nude mice, loose that capacity if TP53INP1 is reexpressed
(Figs. 2 and 3). That observation was extended to E1A/ras-MEFs
which, upon injection into nude mice, also proliferate to form
tumors. When MEFs were derived from TP53INP1/ mice,
tumors grew significantly faster than when they were obtained
from wild type mice or when TP53INP1 had been reexpressed
(Fig. 4). Obtaining similar results with two very different models
of xenografted tumors strongly supports the idea that TP53INP1
expression possesses tumor suppressor properties.
Pancreatic cancer is an epigenetic and genetic disease. Studies
on the mechanisms by which genes are inactivated during
pancreatic cancer progression revealed that they involved mu-
tations (e.g., K-ras, p53) or alterations of DNAmethylation (e.g.,
p16, cyclin D2) (1). Our results suggest that, contrary to these
genes, TP53INP1 is neither mutated nor hypermethylated during
pancreatic cancer. Surprisingly, TP53INP1 mRNA levels in
tumors and in adjacent normal tissue were similar, whereas the
protein, present in normal tissue, was undetectable in PDAC.
This observation points toward a translational or posttransla-
tional regulation of TP53INP1 expression.
Recently, miRNAs have been described as small, siRNA-like
molecules, encoded in the genome and regulating gene expres-
sion by binding specific mRNAs and modulating their transla-
tion. Several reports have shown that the expression levels of
some miRNAs are modified during tumor progression, suggest-
ing links between miRNAs and cancer (29, 30). For this reason
we investigated the possibility that miRNAs are involved in
TP53INP1 loss. A computer search for miRNA targets in the
TP53INP1 3 UTR sequence revealed the presence of a region
with significant complementarity with miR-155. That 3 UTR
region is extremely conserved among different species (Fig. 5)
suggesting a functional role. A remarkable feature of miR-155 is
its conservation during evolution, as shown by the high degree
of similarity between the mouse, rat and human orthologs (Fig.
5). Therefore, miR-155 seems to be a functional miRNA and not
an artifact of in silico genomics. This statement is supported by
data reported above (Fig. 5) showing that miR-155 could indeed
inhibit TP53INP1 expression.
Interestingly, miR-155 is up-regulated in different neoplasms
such as Burkitt lymphoma (31), classical Hodgkin disease,
primary mediastinal, diffuse large-cell lymphoma (32), B cell
chronic lymphocytic leukemia (33) and in lung (34) and breast
cancer (35). Costinean et al. (36) have recently shown in a
transgenic mouse model that selective overexpression of miR-
155 in B cells induces early B cell polyclonal proliferation
followed by high-grade lymphoma-pre-B leukemia. This report
shows that amiRNA can induce by itself a neoplastic disease and,
consequently, be considered as an oncogene (18, 19). In addi-
tion, two studies have recently shown that miR-155 is overex-
pressed in PDAC. Szafranska et al. (17) monitored alterations of
miRNA expression in pancreatic cancer and observed a 10-fold
increase in miR-155 expression. Independently Lee et al. iden-
tified a miRNA signature in pancreatic cancer in which miR-155
is up-regulated 14 times in PDAC and is among the 20 miRNAs
whose expression is altered the most between normal and cancer
(16).
The fact that up-regulation of this miRNA is associated with
lymphoma, leukemia and with several solid cancers suggests a
broad oncogenic function. Data not shown might indicate that
one or more of its targets could be genes linked to a process that
is commonly lost in all cancers, irrespective of their origin. The
mechanism by which miR-155 acts as an oncogene is unknown.
An interesting suggestion is that it could knock down expression
of anti-tumoral proteins (37). TP53INP1, by its anti-tumoral
activity, could be one of these target genes. This hypothesis is
very exciting because TP53INP1 is a previously undescribed
miR-155 target with anti-tumoral activity.
Materials and Methods
Histological, Immunohistochemical, and Immunocytofluorescence
Analyses.Anti-TP53INP1 monoclonal antibody (clone A25-E12)
was used as primary antibody (6 g/ml, overnight incubation) for
immunostaining in paraffin-embedded sections from patient
samples. Detection was done by using Rat ABC Staining system
(Santa Cruz Biotechnology, Santa Cruz, CA) according to the
manufacturer’s instructions. Slides were then counterstained
with hematoxylin (Vector Laboratories, Burlingame, CA) and
mounted by using Eukitt solution. For negative control exper-
iments, anti-TP53INP1 was either replaced by saline or prein-
cubated with recombinant TP53INP1 protein (10 g/ml). The
proportion of positive cells was analyzed.
TP53INP1- and EGFP-inducible MiaPaCa2 cells were plated
on glass coverslips. After a 16-h treatment with 10 M PonA or
vehicle, cells were fixed in PBS 4% formaldehyde, permeabilized
in 0.2% Triton X-100, and incubated with a mouse monoclonal
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anti-GFP antibody (1/800) (Roche, Indianapolis, IN; clones 7.1
and 13.1). The secondary antibody was anti-mouse FITC-
conjugated IgG (1/1,000) (Santa Cruz Biotechnology). Finally,
coverslips were mounted in ProLong Gold antifade reagent with
DAPI (Molecular Probes, Leiden, The Netherlands).
Cell Culture and Treatment.MiaPaCa2, Capan2, 293T, MEFs, and
MCF7 cells were maintained at 37°C and 5% CO2 in DMEM
Glutamax medium (Invitrogen, Groningen, The Netherlands)
supplemented with 10% FBS (Invitrogen) and 1% penicillin/
streptomycin (Invitrogen). Cells’ gamma irradiation was per-
formed at 30 Gy with an IBL 437 Irradiator from CIS BIO
International.
TP53INP1/ and TP53INP1/ MEFs. TP53INP1 deficient mice con-
struction is described in ref. 28. TP53INP1/ and TP53INP1/
MEFs were obtained from embryos derived from homozygous
breeding at 14.5 days postcoitum (E14.5) according to standard
protocol (38), cultured in DMEMGlutamax medium containing
10% FCS, and used at early passages. TP53INP1 genotypes of
cultured MEFs were determined by PCR (Fig. 4A). MEFs were
transformed by transduction with the pBabe-E1A/rasV12 retro-
viral vector (details in SI Materials and Methods).
Measurement of Luciferase Activity. 293T cells were transfected
with a mixture of 0.2 g of Luciferase reporter plasmid con-
struct, 0.2 g of pEGFP plasmid, and the indicated concentra-
tion of miRNA. The miR-155 and miRNA Negative Control #1
(miR-control) were obtained from Ambion (Austin, TX). After
48 h, cells were washed and lysed with Reporter lysis buffer
(Promega, Madison, WI), and firefly Luciferase activity was
determined by using the Luciferase assay system (Promega) and
a luminometer/f luorimeter (Xenius, SAFAS S.A, Monaco). The
Luciferase reporter activity was normalized for transfection
efficiency with the EGFP fluorescence.
Intrapancreatic Tumor Epifluorescence. TP53INP1-EGFP expres-
sion was verified in pancreas by EGFP epifluorescence with a
Leica fluorescentMZFL3 binocular microscope (Leica,Wetzlar,
Germany). Pancreatic tissue was excised, briefly washed in
phosphate saline buffer, and directly observed.
Immunohistochemistry of Active Caspase-3 in Intrapancreatic Tumors.
After deparaffinization and blocking of nonspecific binding,
sections were incubated with an anti-human active-caspase-3
antibody (1:200; Promega). Immunoperoxidase procedure was
performed by using a Vectastain goat anti-rabbit kit (Vector
Laboratories). Active caspase-3 labeled surface was quantified
with an Olympus BX61 automated microscope (10 objective)
by using Samba 2050 image analyzer (Samba Technologies,
Meylan, France).
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